What FDA‑approved non‑stimulant medications are available for treating adult attention‑deficit/hyperactivity disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FDA-Approved Non-Stimulant ADHD Medications for Adults

The FDA-approved non-stimulant medications for adult ADHD are atomoxetine (Strattera), extended-release guanfacine (Intuniv), and extended-release clonidine (Kapvay). 1, 2

Available Non-Stimulant Options

Atomoxetine (Strattera)

  • Mechanism: Selective norepinephrine reuptake inhibitor
  • FDA approval: Approved for both children and adults with ADHD 3, 4
  • Efficacy: Effect size approximately 0.7 (compared to stimulants at 1.0) 2
  • Dosing: Weight-based titration up to maximum 1.4 mg/kg/day or 100 mg/day, whichever is lower 3
  • Onset: 6-12 weeks until full effects observed 3
  • Key advantage: "Around-the-clock" symptom coverage, uncontrolled substance 3

Common adverse effects in adults: Dry mouth, insomnia, nausea, decreased appetite, constipation, urinary retention, erectile dysfunction, dysmenorrhea, dizziness, decreased libido 4

Critical monitoring: Suicidality (especially first few months), clinical worsening, pulse, and cardiovascular parameters 3

Extended-Release Guanfacine (Intuniv)

  • Mechanism: Alpha-2 adrenergic receptor agonist
  • FDA approval: Approved as monotherapy or adjunctive to stimulants 2
  • Efficacy: Effect size approximately 0.7 2
  • Dosing: Once-daily, weight-adjusted (approximately 0.1 mg/kg), available in 1,2,3, and 4 mg tablets 3
  • Onset: 2-4 weeks until effects observed 3

Common adverse effects: Somnolence, fatigue, hypotension, dry mouth 2, 3

Monitoring: Pulse and blood pressure 3

Extended-Release Clonidine (Kapvay)

  • Mechanism: Alpha-2 adrenergic receptor agonist (similar to guanfacine but approximately 10 times more potent) 3
  • FDA approval: Approved as monotherapy or adjunctive to stimulants 2
  • Efficacy: Effect size approximately 0.7 2
  • Dosing: Starting 0.1 mg at bedtime, can increase to twice-daily; maximum 0.4 mg/day. Also available as transdermal patch (0.1,0.2,0.3 mg) 3
  • Onset: 2-4 weeks until effects observed 3

Common adverse effects: Somnolence, sedation, fatigue, hypotension, bradycardia, dry mouth 2, 3

Monitoring: Pulse and blood pressure 3

Clinical Decision Algorithm

When to use non-stimulants as first-line in adults:

  • Comorbid substance use disorders 3
  • Comorbid anxiety disorders requiring 24-hour coverage
  • History of stimulant intolerance or non-response
  • Patient preference for non-controlled substance
  • Cardiovascular contraindications to stimulants (relative)

When to use as adjunctive therapy: Extended-release guanfacine and extended-release clonidine are the only two medications with FDA approval for adjunctive use with stimulants 2

Important Clinical Caveats

Comparative efficacy: All non-stimulants have smaller effect sizes (0.7) compared to stimulants (1.0), meaning they are moderately less effective at reducing core ADHD symptoms 2

Delayed onset: Unlike stimulants which work within hours, atomoxetine requires 6-12 weeks and alpha-2 agonists require 2-4 weeks for full therapeutic effect 3

Dosing pitfall: Subtherapeutic dosing is common and reduces clinical benefit—titrate to maximum recommended doses if symptoms remain insufficiently controlled 5

Discontinuation warning: Alpha-2 agonists should not be stopped abruptly due to risk of rebound hypertension 3

Atomoxetine-specific: Requires monitoring for suicidal ideation, particularly in the first few months of treatment or with dose changes 3. Rare but serious risk of hepatotoxicity 2. Metabolized via CYP2D6, so interactions with SSRIs can elevate levels 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.